Abstracts tagged "Behcet’s syndrome"

Abstract Number: 2732 • 2014 ACR/ARHP Annual Meeting
Massive Ex Vivo Expansion of Functionally Stable Behcet’s Patient-Derived Regulatory T Cell Clones
Johannes Nowatzky¹, Olivier Manches¹, Yusuf Yazici² and Juan Lafaille¹, ¹New York University School of Medicine, New York, NY, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Adoptive transfer of regulatory T cells (Treg) is a promising strategy for the treatment of human autoimmune diseases. Most currently tested approaches focus on…
Abstract Number: 2756 • 2014 ACR/ARHP Annual Meeting
Treatment of Mucocutaneous Manifestations in Behçet’s Disease with Anakinra: A Pilot Open-Label Study
Peter C. Grayson¹, Yusuf Yazici², Elaine Novakovich³, Elizabeth Joyal⁴, Raphaela T. Goldbach-Mansky⁴ and Cailin H. Sibley^3,5, ¹NIAMS Systemic Autoimmunity Branch, National Institutes of Health, Bethesda, MD, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³National Institutes of Health Clinical Center, Bethesda, MD, ⁴NIAMS, National Institutes of Health Clinical Center, Bethesda, MD, ⁵Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR
Background/Purpose: IL-1 blocking therapy shows promise in the treatment of Behçet’s eye disease, but its effect on mucocutaneous manifestations is unknown. Methods: 6 patients with…
Abstract Number: 2208 • 2014 ACR/ARHP Annual Meeting
Ovarian Reserve Alterations in Premenopausal Women with Rheumatoid Arthritis, Behcet’s Disease and Spondyloarthritis – Impact on Anti-Muellerian Hormone Levels
Joerg C. Henes¹, Julia Froeschlin², Andre Taran³, Theodoros Xenitidis⁴ and Melanie Henes⁵, ¹Department of Internal Medicine II, Rheumatology Division, University Hospital Tuebingen, Tuebingen, Germany, ²University Tuebingen, Tuebingen, Germany, ³University Hospital for Women Tuebingen, Tuebingen, Germany, ⁴Internal Medincine II, devision for Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, ⁵University Hospital for Women, Tuebingen, Germany
Background/Purpose: Recent publications showed a negative influence of systemic lupus erythematosus and antiphospholipid antibody syndrome on female ovarian reserve (OR). Other authors did not find…
Abstract Number: 2757 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of ANTI-TNF ALPHA in BEHÇET Disease: A International Multicenter Registry of 122 Patients
Hélène Vallet¹, Sophie Rivière², Alban Deroux³, Guillaume Moulis⁴, Olga Addimanda⁵, Carlo Salvarani⁶, Marc Lambert⁷, Philip Bielfeld⁸, Pascal Sève⁹, Jean Sibilia¹⁰, Jean Baptiste Fraison¹¹, Yoland Schoindre¹², Isabelle Marie¹³, Laurent Perard¹⁴, Thomas Papo¹⁵, Damien Sène¹⁶, Gaelle Leroux¹⁷, Valerie Royant¹⁸, Antoinette Perlat¹⁹, Xavier Mariette²⁰, Olivier Lidove²¹, Olivier Fain²², Claire De Moreuil²³, Gilles Blaison²⁴, Phuc LE Hoang²⁵, Eric Hachulla²⁶, Bertrand Wechsler²⁷, Barham Bodaghi²⁸, Patrice Cacoub²⁹ and David Saadoun³⁰, ¹Internal medicine, DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ²Internal Medicine, Lapeyronie, Montpellier, France, ³Internal Medicine, CHU Grenoble, Grenoble, France, ⁴Internal Medicine department, Toulouse, Toulouse, France, ⁵S.C. Reumatologia, Arcispedale Santa Maria Nuova, I.R.C.C.S., Reggio Emilia, Italy, ⁶Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ⁷CHRU Lille, Lille, France, ⁸CHU de Dijon, Dijon, France, ⁹Internal medicine, CHU Lyon, Lyon, France, ¹⁰Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ¹¹Hôpital Jean Verdier, Bondy, France, ¹²DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, PARIS, France, ¹³CHU de Rouen, Rouen, France, ¹⁴Hospices civils de Lyon, Lyon, France, ¹⁵Hôpital Bichat, Paris, France, ¹⁶Hopital Lariboisière, service de Médecine Interne, Paris, France, ¹⁷Department of Internal Medicine and Clinical Immunology, Hospital University Department: inflammation, immunopathology and biotherapy (DHU i2B), DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ¹⁸Chartres, Chartres, France, ¹⁹Internal medicine, CHU de Rennes, Rennes, France, ²⁰rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France, ²¹Médecine interne, Hôpital Croix-Saint-Simon, PARIS, France, ²²Hôpital Saint Antoine, DHU i2B, Service de Médecine Interne, paris, France, ²³CHU, Brest, France, ²⁴Internal medicine, CHR, Colmar, France, ²⁵Ophtalmology, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié Salpétrière, Paris, France, ²⁶Internal Medicine, National Scleroderma Centre, Lille CEDEX, France, ²⁷Internal Medicine, DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ²⁸Ophtalmology, Hôpital de la Pitié Salpêtrière, Paris, France, ²⁹Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, ³⁰DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France
Background/Purpose Behçet’s disease (BD) is a systemic large vessel vasculitis with recurrent genital and oral ulceration, uveitis, cardiovascular, joints, neurological or gut symptoms. Treatment of…
Abstract Number: 1339 • 2014 ACR/ARHP Annual Meeting
Is Psychological Status Related to Symptom Experience in Behçet’s Syndrome?
Robert Moots¹ and Sophie Campbell², ¹Musculoskeletal Biology, University of Liverpool, Liverpool, United Kingdom, ²Behcets Centre, Aintree University Hospital, Liverpool, United Kingdom
Background/Purpose Little is known about the impact of Behçet’s Syndrome (BS) within the UK. The recent establishment of National Centres of Excellence now allows a…
Abstract Number: 2758 • 2014 ACR/ARHP Annual Meeting
Predictive Factors for the Response to Infliximab Therapy in Patients with Behçet’s Disease
Salvatore D'Angelo¹, Pietro Leccese¹, Angela Padula¹, Angelo Nigro¹, Michele Gilio², Antonio Carriero¹, Carlo Palazzi¹ and Ignazio Olivieri¹, ¹Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy, ²San Carlo Hospital, Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy
Background/Purpose: To identify the clinical factors predicting a good clinical response to Infliximab (IFX) therapy after 12 months in patients with Behçet’s disease (BD) refractory…
Abstract Number: 1212 • 2014 ACR/ARHP Annual Meeting
Behcets Disease in Females Due to Mutation in NEMO, the NF-Kb Essential Modulator
Alex Wessel¹, Spiros Vonortas², Jevgenia Zilberman-Rudenko³, Richard Siegel⁴ and Eric Hanson⁵, ¹5814 Beech Ave, NIH, Bethseda, MD, ²NIH, NIAMS, Bethesda, MD, ³Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴NIAMS, NIH, Bethesda, MD, ⁵National Institute of Health, Bethesda, MD
Background/Purpose: Behçet's disease (BD) is a chronic multi-system inflammatory disorder associated clinically with oral and genital ulceration, uveitis, erythema nodosum, and other inflammatory disease. The…
Abstract Number: 2760 • 2014 ACR/ARHP Annual Meeting
Interferon Alfa-Associated Depression in Patients with Behçet’s Syndrome
Yasin Keskin¹, Emire Seyahi², Cagri Poyraz³, Serdal Ugurlu¹, Yilmaz Ozyazgan⁴ and Hasan Yazici⁵, ¹Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Division of Rheumatology,Department of Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ³Department of Psychiatry, Cerrahpasa Medical Faculty, University Of Istanbul, Istanbul, Istanbul, Turkey, ⁴Department of Ophthalmology, Cerrahpasa Medical Faculty University of Istanbul, Istanbul, Turkey, ⁵Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey
Background/Purpose: Interferon (IFN) is an effective immune-modulatory agent in the medical management of eye disease of Behçet’s syndrome (BS). The agent is frequently associated with…
Abstract Number: 2762 • 2014 ACR/ARHP Annual Meeting
Atrophy of Hippocampal Region in Chronic Progressive Neuro-Behçet’s Disease
Hirotoshi Kikuchi¹, Kurumi Asako¹, Maki Takayama¹, Yoshitaka Kimura¹, Akiko Okamoto¹, Toshihiro Nanki^1,2, Hajime Kono¹ and Shunsei Hirohata³, ¹Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ²Department of Clinical Research Medicine, Teikyo University, Tokyo, Japan, ³Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose: Central nervous system involvement in Behçet's disease, usually called neuro-Behçet's disease (NB), can be classified into acute NB (ANB) and chronic progressive NB (CPNB)…
Abstract Number: 2763 • 2014 ACR/ARHP Annual Meeting
Long-Term Outcome of Chronic Progressive Neurological Manifestations in Behcet’s Disease
Shunsei Hirohata¹, Hirotoshi Kikuchi², Tetsuji Sawada³, Hiroko Nagafuchi⁴, Msataka Kuwana⁵, Mitsuhiro Takeno⁶ and Yoshiaki Ishigatsubo⁷, ¹Int Med/Rheumatol & Infec Dis, Kitasato Univ School of Med, Kanagawa, Japan, ²Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ³Internal Medicine 3, Tokyo Medical University, Tokyo, Japan, ⁴Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan, ⁵Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁶Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan, ⁷Int Med & Clin Immunology, Yokohama City Grad Schl of Med, Yokohama, Japan
Background/Purpose: Chronic progressive neurological manifestations in Behcet's disease (BD) is characterized by progressive deterioration leading to disability either with or without a history of previous…
Abstract Number: 2744 • 2014 ACR/ARHP Annual Meeting
Mi-RNA Profile of Active Vascular BEHÇET’S Patients
Ahmet Mesut Onat¹, Ozan Gerenli², Bunyamin Kisacik¹, Mustafa Ulasli³, Gezmis Kimyon⁴, Yavuz Pehlivan⁵ and Serdar Oztuzcu⁶, ¹Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ²Rheumatology, Gaziantep UniversitySchool of Medicine, Gaziantep, Turkey, ³Genetics, Gaziantep UniversitySchool of Medicine, Gaziantep, Turkey, ⁴Department of Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁵Rheumatology, Uludag University, School of Medicine, Bursa, Turkey, ⁶Genetcs, Gaziantep UniversitySchool of Medicine, Gaziantep, Turkey
Background/Purpose Behçet’s Disease (BD) is a systemic vasculitis that predominantly presented with oral aphtous ulcers and additionally at least two of the following findings like…
Abstract Number: 2745 • 2014 ACR/ARHP Annual Meeting
Plasma of Patients with Active Behçet´s Disease (BD) Increases Neutrophil Extracellular Trap Formation, Oxidative Metabolism and NADPH-Oxidase Expression in Normal and BD Neutrophils, and Carries Several Neutrophil Stimulating Factors
Sandro F. Perazzio^1,2, Paulo Vitor Soeiro Pereira³, Alexandre W. S. de Souza¹, Antonio Condino-Neto³ and Luis Eduardo C. Andrade^2,4, ¹Rheumatology, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, ²Fleury Medicine and Health, Sao Paulo, Brazil, ³Immunology, ICB IV - Universidade de São Paulo, São Paulo, Brazil, ⁴Fleury Laboratories, Sao Paulo, Brazil
Background/Purpose Plasma factors seem to play a role in Behçet’s disease (BD) pathogenesis, especially by increasing phagocyte oxidative profile. No data exists regarding neutrophil extracellular…
Abstract Number: 2747 • 2014 ACR/ARHP Annual Meeting
Identification of Potential Serum Biomarkers for Behcet Disease By High Resolution Quantitative Proteomic Analysis
Yongjing CHENG Jr.¹, Xiaolin Sun², Yuling Chen Jr.³, Cibo Huang⁴, Haiteng Deng³ and Zhan-Guo Li⁵, ¹Rheumatology and Immunology Department, Beijing Hospital, Ministry of Health, Beijing, China, ²People's hospital,Peking University, Beijing, China, ³Tsing hua University, Beijing, China, ⁴Beijing hospital, Beijing, China, ⁵Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China
Background/Purpose: Behcet’s disease (BD) is a chronic, multisystemic vasculitis, pathogenesis of BD remains enigmatic. Diagnosis of BD is sometimes difficult, and until now, no specific…
Abstract Number: 2748 • 2014 ACR/ARHP Annual Meeting
Microparticles May Play a Role in Causing Thrombosis in Behçet’s Syndrome and Act As a Biomarker for Risk Management
Emon Khan¹, Nicola Ambrose¹, Michael A. Laffan² and Dorian O. Haskard³, ¹Department of Vascular Sciences, National Heart and Lung Institute, Imperial College, London, United Kingdom, ²Department of Haemostasis and Thrombosis, Imperial College, London, United Kingdom, ³Rheumatology, Imperial College, London, United Kingdom
Background/Purpose Thrombosis occurs in 20% of patients with Behçet’s Syndrome (BS) and leads to significant morbidity. There is no robust association between thrombosis in BS…
Abstract Number: 2620 • 2013 ACR/ARHP Annual Meeting
Development Of De Novo Major Involvement During The Follow-Up In Behçet’s Disease
Claudia Ferrari¹, Rosaria Talarico², Chiara Stagnaro³, Anna d'Ascanio⁴, Chiara Tani³, Chiara Baldini³, Marta Mosca¹ and Stefano Bombardieri³, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Rheumatology Unit, Pisa, Italy, ³University of Pisa, Rheumatology Unit, Pisa, Italy, ⁴Malattie muscolo-scheletriche e cutanee, Rheumatology Unit, Pisa, Italy
Background/Purpose: Behçet’s disease (BD) is globally characterized by a variable spectrum of disease profile: while prevalent muco-cutaneous lesions and arthritis represent the only clinical features…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].